Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
Tóm tắt
Biliary tract cancers (BTC) have a poor prognosis, and there is no consensus on the best chemotherapy regimen. This study determined the response rate for fixed-dose-rate (FDR) gemcitabine combined with cisplatin. This multicentre phase II trial enrolled 50 patients with inoperable locally advanced or metastatic BTC. Treatment consisted of FDR gemcitabine 1,000 mg/m2 (10 mg/m2/min) and cisplatin 20 mg/m2 on days 1 and 8 of a 21-day cycle. The primary endpoint was response rate. Secondary endpoints included safety, response duration (RD), progression-free (PFS) and overall survival (OS), and cancer antigen 19-9 response. Thirteen patients (26%, 95% CI 14.6–40.4) had a partial response, and 12 (24%) had stable disease. The median RD was 8.3 months (95% CI 6.91–9.99); median PFS 4 months (95% CI 2.5–6.77); and median OS 6.8 months (95% CI 5.0–8.7). Treatment was well tolerated. Grade 3 and grade 4 nausea, vomiting, and fatigue were uncommon. Thirty-eight per cent of patients discontinued treatment because of toxicity, patient or clinician preference. This treatment combination had moderate activity with acceptable toxicity, supporting previous results that this combination has a role to play. The study does not suggest that FDR gemcitabine is superior to bolus infusion.
Tài liệu tham khảo
Greenlee RT, Hill-Harmon MB, Murray T et al (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36
Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10
Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902
Pasetto LM, D’Andrea MR, Falci C et al (2007) Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol Haematol 61:230–242
Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and pharmacology study of gemcitabine. J Clin Oncol 9:491–498
Tempero M, Plunkett W, van Haperen VR et al (2003) Randomised phase II comparison of fixed dose-intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408
Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology. J Clin Oncol 27:3778–3785
Peters GJ, Bergman AM, Ruiz van Haperen VW et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72–79
Van Moorsel CJ, Pinedo HM, Veerman G et al (1999) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer 80:981–990
Valle JW, Wasan HS, Palmer DD et al (2009) Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer: results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 27:15s (abstract 4503)
Ko A, Dito E, Schillinger B et al (2006) Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24:379–385
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
Rustin GJ, Nelstrop AE, McClean P et al (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545–1551
Meyerhardt JA, Zhu A, Stuart K et al (2008) Phase II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 53:564–570
Lee J, Kim TY, Lee MA et al (2008) Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 61:47–52
Giuliani F, Gebbia V, Maiello E et al (2006) Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicentre phase II study of the Gruppo Oncologica dell’Italia Meridionale. Ann Oncol 17:vii73–vii77
Park BK, Kim YJ, Park JY et al (2006) Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastronenterol Hepatol 21:993–1003
Kim ST, Park JO, Lee J et al (2006) A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339–1346
Thongprasert S, Napapan S, Charoentum C et al (2005) Phase II study of gemcitabine and cisplatin as first line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279–281
Doval DC, Sekhon JS, Gupta SK et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy naïve, unresectable gallbladder cancer. Br J Cancer 90:1516–1520
Reyes-Vidal J, Gallardo J, Yanez E et al (2003) Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study. Proc Am Soc Clin 22:273 abstract 1095
Lee GW, Kang JH, Kim HG et al (2006) Combination chemotherapy with gemcitabine and cisplatin as first line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 29:127–131
Ko AH, Hwang J, Venook AP et al (2005) Serum CA19–9 response as a surrogate for clinical outcome in patients receiving fixed dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93:195–199
Harder J, Kummer O, Olschewski M et al (2007) Prognostic relevance of Carbohydrate Antigen 19.9 levels in patients with advanced biliary tract cancer. Cancer Epidemiol Biomarkers Prev 16:2097–2100
Riechelmann RP, Townsley CA, Chin SN et al (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307–1312
Iyer RV, Gibbs J, Kuvshinoff B et al (2007) A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder. A single institution study. Ann Surg Oncol 14:3202–3209
Andre T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin in advanced biliary tract adenocarcinoma. A GERCOR study. Ann Oncol 15:1339–1343
Verderame F, Russo A, Di Leo R et al (2006) Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 17(suppl 7):68–72
Park SH, Park YH, Lee JN et al (2006) Phase II study of epirubicin, cisplatin and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106:361–365